TORONTO, Canada, September 13, 2016 – Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of transformative biomedical-polymer technologies that improve the safety and effectiveness of medical devices, is pleased to announce the addition of Wendy Naimark, PhD, to the IBI management team, as Vice President of Research & Development.
Wendy joins IBI after serving for five years as Senior Director, Clinical and Preclinical Sciences at 480 Medical, an early stage drug delivery device company in the cardiovascular space. Previously, she spent 11 years at Boston Scientific in increasingly senior management and R&D roles in the areas of Interventional Cardiology, Peripheral Interventions, Imaging, Endosurgery, Urology/Women’s health and Neuurovascular. Wendy completed her MSc and PhD at the University of Toronto in Biomaterials. She was also a Post Doctoral Fellow at both the University of Massachusetts at Amherst and the California Institute of Technology. She is the inventor of 27 US patents and author of 12 peer-reviewed publications.
“We are very pleased to have Wendy join our growing team”, stated Tom Reeves, President and C.E.O. of Interface Biologics, Inc. “It’s rare that you find such a capable scientist with experience in both large medical device companies and early stage startups. We look forward to her leadership as our new V.P. of R&D.”
"I have watched Wendy achieve great strides over the past two decades in the medical device field since completing her PhD at the University of Toronto in the early 90's”, commented Dr. Paul Santerre, Chief Scientific Officer, IBI. “And now Interface Biologics has a V.P. of Research and Development with broad scientific knowledge and two decades of deep insight and experience in the medical device world. We are so pleased to have her at the forefront to help chart the next generation of IBI products."
“I couldn't be more thrilled to take on the exciting challenges ahead”, stated Dr. Wendy Naimark, new V.P., R&D at IBI. “I have very fond memories of Dr. Santerre’s groundbreaking work at the University of Toronto, Faculty of Dentistry and have been following it’s growth through Interface Biologics. Having the opportunity to join Tom and the IBI team at this point in the company’s trajectory, is an exciting opportunity and one I fully embrace. I am laser-focused on leveraging my 16 years of stateside product development experience to drive, guide and inspire our team.”
About Interface Biologics, Inc. Interface Biologics (IBI) is an early commercial stage privately held company that develops transformative biomedical polymer technologies that improve the safety and effectiveness of medical devices. IBI’s primary technology focus areas are anti-thrombogenic additives that reduce thrombosis in blood contacting medical devices and polymer enabled drug delivery platforms. www.interfacebiologics.com.
Julie Fotheringham, Partner, Hageman Communications